Form 13G’s must be filed with the SEC upon any investor or entity amassing at least 5% of a company’s outstanding shares, or alternatively, an investment falling beneath the 5% ownership threshold. Investors should closely monitor this filing activity, as it represents the trading activity of some of the company’s biggest supporters, who have doubtlessly done an immense amount of research on the company and its sector and have a good understanding of its value and potential. Below we have embedded just such a filing, issued by James Flynn‘s Deerfield Management on Editas Medicine Inc (NASDAQ:EDIT), which had its IPO earlier this month and which has 5.07% of its shares owned by Deerfield now.
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ) *
Editas Medicine, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
February 2, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
(Page 1 of 11 Pages)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Editas Medicine Inc.Follow Editas Medicine Inc.
$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now
The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)